Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Posterior instrumented spinal surgery patients 18 years of age and older with instrumented fusion of at least three vertebral levels~   1. Revision, elderly, obese, and diabetic patients will not be excluded since these patients are known to be at higher risk of wound infection and represent an important fraction of the elective surgical patient population.~2. Patients requiring IV Vancomycin for infection prophylaxis (i.e. due to cephalosporin allergy) will be eligible for participation in the IV Vancomycin group.~Exclusion Criteria:~Intrasite Vancomycin Study Arm Exclusion Criteria~1. Children under 18 years old~2. Patients not receiving instrumentation or having less than three segment surgery~   - therefore having small wound bed surface areas, close operative quarters, and lower infection risk.~3. Patients not receiving wound drains~   * drains provide the conduit for seroma fluid collection~4. Patients with known or suspected current infection~5. Use of systemic or topical antibiotics within 72 hours prior to surgery~   * other than standard pre-op dose of ancef~6. Use of drugs or medications known to significantly increase the risk of renal toxicity within the perioperative period.~7. Patients with known significant allergy to Vancomycin~   - Redman Syndrome patients will not be excluded~8. Use of IV Vancomycin for perioperative infection prophylaxis (for example, in cases of penicillin/cephalosporin allergy) will exclude patients from participation in the intrasite Vancomycin groups of the study.~   * IV Vancomycin Study Arm Exclusion Criteria~<!-- -->~1. Children under 18 years old~2. Patients not receiving instrumentation or having less than three segment surgery - therefore having small wound bed surface areas, close operative quarters, and lower infection risk.~3. Patients not receiving wound drains~   - drains provide the conduit for seroma fluid collection~4. Patients with known or suspected current infection~5. Use of systemic or topical antibiotics within 72 hours prior to surgery~   * other than study related IV Vancomycin~6. Use of drugs or medications known to significantly increase the risk of renal toxicity within the perioperative period.~7. Patients with known significant allergy to Vancomycin~   * Redman Syndrome patients will not be excluded~8. Use of intrasite Vancomycin for infection prophylaxis will exclude patients from participation in the IV Vancomycin study group.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose Intrasite Vancomycin (Type: EXPERIMENTAL): 10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
- Mid-dose Intrasite Vancomycin (Type: EXPERIMENTAL): 10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
- High-dose Intrasite Vancomycin (Type: EXPERIMENTAL): 10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
- Optimally-dosed IV Vancomycin (Type: ACTIVE_COMPARATOR): 10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval